Programmed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study

Ayoub, Nehad M.; Fares, Mohammad M.; Marji, Raya; Bashir, Samir M Al; Yaghan, Rami J.

doi:10.2147/bctt.s333123

Cited by 1 publication

(3 citation statements)

References 60 publications

(97 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, we found that there is an insignificant link between the age of patients and PD-L1's expression, this comes in concordance with a conclusion by Ayoub in the same studies [11,19]; moreover, data from cBioPortal-TCGA, PanCancer Atlas that retrieved from 1082 patients' samples diagnosed with invasive breast carcinoma, presented that the correlation between age and PD-L1 expression at the level of mRNA (CD274 gene mRNA expression) was insignificant indicating that expression of PD-L1 is not linked to how young or old is the subject, in other words, age is not a factor that underlines the level of expression, and this supports the same conclusion we made around the variable [20,21].…”

Section: Discussionsupporting

confidence: 93%

“…In this study, PD-L1 was expressed in rates of 30% which seems to be in a reasonable range among studies held on whole tissue section [11,17,18]. In general terms, there is a considerable discrepancy between rates of PD-L1 expression as there is no standardized method for scoring beside variable cut-off points for PD-L1 positivity [12].…”

Section: Discussionmentioning

confidence: 58%

“…Hence, TILs and tumor PD-L1 overexpression may be functionally related [10]. On the other hand, PD-L1 expression has been strongly correlated with unfavorable clinicopathologic characteristics of BC [11].…”

Section: Introductionmentioning

confidence: 97%

See 2 more Smart Citations

Expression of Programmed Death Ligand-1 and Correlation with Clinicopathological Features and CD8 Infiltration in Breast Cancer

Salih,

Abdelaziz,

Mosad

et al. 2023

SJMS

View full text Add to dashboard Cite

Background: Breast cancer (BC) is considered one of the most diversified types of tumors, characterized by a high mutational burden in the tumor milieu and a lack of immune cell makeup. The programmed death receptor-1 (PD -1)/programmed death ligand-1 (PD -L1) axis has been identified as a new target in the field of immunotherapy because, when activated, they worsen the future scenarios of the disease by helping tumor cells (TC) to escape immune surveillance. This study aims to investigate the expression of PD-L1 in BC tissues from Sudanese women and correlate the expression with clinicopathological features and the infiltration of CD8+T lymphocytes by immunohistochemistry (IHC). Methods: One hundred and fifty archived BC blocks were collected from the National Public Health Laboratory from January 2019 to August 2020. Data regarding age, TNM staging, grade, and hormonal status were considered. Tissue sections were examined using IHC to determine the expression of PD-L1 and CD8. Results: Among one hundred and fifty BC samples, 73 (48.7%) were TNBCs, and 77 (51.3%) were hormone-positive BCs. PDL-1 was significantly associated with BC subtypes, especially TNBCs (P = 0.001), a similar significant association was shown with CD8 infiltration (P = 0.006). None of the clinicopathological features was associated with PD-L1 expression. Conclusion: PD-L1 expression is strongly associated with TNBC’s and linked to CD8+ cells infiltration to the tumor milieu. Moreover, no correlation has been observed between the expression of PD-L1 and clinicopathological features in this study.

show abstract